ArticleInfection and immunity2001
Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.
Article in Infection and immunity, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 47 citations in OpenAlex.
- Safety and Immunogenicity of a Trivalent Salmonella Conjugate Vaccine to S. Typhi, S. Typhimurium, and S. Enteritidis.The Journal of infectious diseases · 2026Trial
- A TonB dependent transporter YncD of Salmonella enterica Serovar Typhi possesses vaccine potential.World journal of microbiology & biotechnology · 2024Article
- Recombinant AttenuatedCancers · 2022Review
- Immunogenicity and Efficacy of Live-AttenuatedInfection and immunity · 2021Article
- Crosstalk between leukocytes triggers differential immune responses against Salmonella enterica serovars Typhi and Paratyphi.PLoS neglected tropical diseases · 2019Article
- Cell mediated immune responses elicited in volunteers following immunization with candidate live oral Salmonella enterica serovar Paratyphi A attenuated vaccine strain CVD 1902.Clinical immunology (Orlando, Fla.) · 2019Article
- Improving Our Understanding ofmSphere · 2018Article
- Manipulation ofFrontiers in immunology · 2018Article
- Cancer Immunotherapy: Priming the Host Immune Response with Live AttenuatedJournal of immunology research · 2018Review
- Animal Models for Salmonellosis: Applications in Vaccine Research.Clinical and vaccine immunology : CVI · 2016Review
- An Oral Salmonella-Based Vaccine Inhibits Liver Metastases by Promoting Tumor-Specific T-Cell-Mediated Immunity in Celiac and Portal Lymph Nodes: A Preclinical Study.Frontiers in immunology · 2016Article
- Serum bactericidal assays to evaluate typhoidal and nontyphoidal Salmonella vaccines.Clinical and vaccine immunology : CVI · 2014Article
- Inactivation of the Rgg2 transcriptional regulator ablates the virulence of Streptococcus pyogenes.PloS one · 2014Article
- Novel methods for expression of foreign antigens in live vector vaccines.Human vaccines & immunotherapeutics · 2013Article
- Efficiency of purine utilization by Helicobacter pylori: roles for adenosine deaminase and a NupC homolog.PloS one · 2012Article
- Cell-associated flagella enhance the protection conferred by mucosally-administered attenuated Salmonella Paratyphi A vaccines.PLoS neglected tropical diseases · 2011Article
- Engineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strains.Infection and immunity · 2011Article
- Immunology of gut mucosal vaccines.Immunological reviews · 2011Review
- Rationally designed tularemia vaccines.Expert review of vaccines · 2009Review
- Identification of genes contributing to the virulence of Francisella tularensis SCHU S4 in a mouse intradermal infection model.PloS one · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 3 countries.
Funding
Abstract
A promising live attenuated typhoid vaccine candidate strain for mucosal immunization was developed by introducing a deletion in the guaBA locus of pathogenic Salmonella enterica serovar Typhi strain Ty2. The resultant DeltaguaBA mutant, serovar Typhi CVD 915, has a gene encoding resistance to arsenite replacing the deleted sequence within guaBA, thereby providing a marker to readily identify the vaccine strain. CVD 915 was compared in in vitro and in vivo assays with wild-type strain Ty2, licensed live oral typhoid vaccine strain Ty21a, or attenuated serovar Typhi vaccine strain CVD 908-htrA (harboring mutations in aroC, aroD, and htrA). CVD 915 was less invasive than CVD 908-htrA in tissue culture and was more crippled in its ability to proliferate after invasion. In mice inoculated intraperitoneally with serovar Typhi and hog gastric mucin (to estimate the relative degree of attenuation), the 50% lethal dose of CVD 915 (7.7 x 10(7) CFU) was significantly higher than that of wild-type Ty2 (1.4 x 10(2) CFU) and was only slightly lower than that of Ty21a (1.9 x 10(8) CFU). Strong serum O and H antibody responses were recorded in mice inoculated intranasally with CVD 915, which were higher than those elicited by Ty21a and similar to those stimulated by CVD 908-htrA. CVD 915 also elicited potent proliferative responses in splenocytes from immunized mice stimulated with serovar Typhi antigens. Used as a live vector, CVD 915(pTETlpp) elicited high titers of serum immunoglobulin G anti-fragment C. These encouraging preclinical data pave the way for phase 1 clinical trials with CVD 915.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.